Cellebrite/$CLBT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Cellebrite
Cellebrite DI Ltd provides AI-powered digital investigative and intelligence solutions that help public and private sector customers transform investigative workflows, make digital data more accessible and actionable, and improve the efficiency of mobile research and application security. Its solutions support law enforcement, defense, and intelligence agencies in advancing investigations, border security, counterterrorism, intelligence operations, and cyber operations. The company's software also enables enterprises and service providers to collect and review data for corporate investigations, eDiscovery, incident response, and mobile application validation. It operates in the Americas, APAC, and EMEA, with the majority of revenue from the Americas.
- Ticker
- $CLBT
- Sector
- Software & Cloud Services
- Primary listing
- NASDAQ
- Employees
- 1,285
- Headquarters
- Petah Tikva, Israel
- Website
- www.cellebrite.com
Cellebrite Metrics
BasicAdvanced
$2.8B
48.78
$0.23
1.15
-
Price and volume
Market cap
$2.8B
Beta
1.15
52-week high
$19.98
52-week low
$9.58
Average daily volume
2.7M
Financial strength
Current ratio
1.619
Quick ratio
1.519
Long term debt to equity
0.033
Total debt to equity
0.043
Profitability
EBITDA (TTM)
78.427
Gross margin (TTM)
82.96%
Net profit margin (TTM)
11.43%
Operating margin (TTM)
10.86%
Effective tax rate (TTM)
22.05%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
3.92%
Return on equity (TTM)
12.42%
Valuation
Price to earnings (TTM)
48.777
Price to revenue (TTM)
5.352
Price to book
5.22
Price to tangible book (TTM)
9.47
Price to free cash flow (TTM)
21.41
Free cash flow yield (TTM)
4.67%
Free cash flow per share (TTM)
0.523
Growth
Revenue change (TTM)
17.76%
Earnings per share change (TTM)
-134.98%
3-year revenue growth (CAGR)
20.54%
3-year earnings per share growth (CAGR)
-0.42%
What the Analysts think about Cellebrite
Analyst ratings (Buy, Hold, Sell) for Cellebrite stock.
Analyst projections of the future price of Cellebrite stock.
Bulls say / Bears say
Recurring momentum remains solid: second-quarter ARR rose 21% to $507.8 million and revenue grew 16%, while net retention reached 117%. Management also raised its adjusted EBITDA target, pointing to continued operating discipline. (FT.com)
Genesis has early signs of adoption, with more than 800 users across 300 agencies during its early-access phase. Its expansion into enterprise and additional markets gives Cellebrite a route to sell AI investigation tools beyond North American public safety. (Cellebrite, Cellebrite)
FedRAMP High authorisation for Cellebrite Government Cloud could make it easier for US federal agencies to procure its cloud tools. That may widen the market for its evidence management and digital forensics products. (Cellebrite)
Cellebrite missed its second-quarter ARR target and lowered its full-year ARR and revenue outlook, citing slower Inseyets expansions. This weakens confidence in the near-term growth trajectory despite healthy reported year-on-year growth. (FT.com)
The new CEO was appointed as Cellebrite reset its outlook, and said the company needed greater urgency in AI and cloud. The leadership change adds execution uncertainty while the company works to restore growth. (FT.com)
Bloomberg reported that Russian authorities used Cellebrite technology to help prosecute a pro-democracy activist. The case highlights rights-related reputational risk that could prompt scrutiny of the company’s government customers or sales. (Bloomberg)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2026.
Cellebrite Financial Performance
Revenues and expenses
Cellebrite Earnings Performance
Company profitability
Upcoming events
No upcoming events
Cellebrite News
AllArticlesVideos
CLBT INVESTIGATION: Cellebrite Investigated by Block & Leviton; Investors Should Contact the Firm to Possibly Recover Losses
Newsfile Corp4 days ago
Kaplan Fox Urges Investors of Cellebrite DI Ltd. (CLBT) with Losses to Contact the Firm
Newsfile Corp4 days ago
Kaplan Fox Reminds Investors of Cellebrite DI Ltd. (CLBT) of an Ongoing Securities Investigation
Newsfile Corp6 days ago
Funds containing Cellebrite
AllUSDEURGBP
Fund name | Fund size | $CLBT weighting |
|---|---|---|
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
iShares MSCI World Small Cap£WLDS | £6.7B | 0.01% |
Amundi Prime All Country World€WEBN | €3.2B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.